A. Mears

409 total citations
11 papers, 284 citations indexed

About

A. Mears is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cognitive Neuroscience. According to data from OpenAlex, A. Mears has authored 11 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 2 papers in Cognitive Neuroscience. Recurrent topics in A. Mears's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). A. Mears is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). A. Mears collaborates with scholars based in United States. A. Mears's co-authors include Mark A. Socinski, Thomas A. Hensing, Julian Rosenman, Jan Halle, David E. Morris, Dominic T. Moore, M. Patricia Rivera, Robert Fraser, Frank C. Detterbeck and Steven Limentani and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Lung Cancer.

In The Last Decade

A. Mears

11 papers receiving 274 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
A. Mears 198 88 68 66 55 11 284
Sophie C.J. Bosma 53 0.3× 102 1.2× 64 0.9× 19 0.3× 46 0.8× 12 264
Antoine Engelen 79 0.4× 78 0.9× 17 0.3× 12 0.2× 31 0.6× 6 178
Zaker Rana 81 0.4× 32 0.4× 37 0.5× 14 0.2× 2 0.0× 37 183
W. Hamilton Williams 555 2.8× 15 0.2× 253 3.7× 10 0.2× 44 0.8× 19 659
Nathan Farrokhian 37 0.2× 31 0.4× 3 0.0× 8 0.1× 14 0.3× 22 167
Josep Jové 239 1.2× 84 1.0× 11 0.2× 35 0.5× 17 302
Eva Clemens 52 0.3× 86 1.0× 25 0.4× 97 1.8× 11 252
Bhisham Chera 40 0.2× 43 0.5× 55 0.8× 3 0.0× 32 253
Matthias Mäurer 23 0.1× 43 0.5× 31 0.5× 61 0.9× 27 216

Countries citing papers authored by A. Mears

Since Specialization
Citations

This map shows the geographic impact of A. Mears's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Mears with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Mears more than expected).

Fields of papers citing papers by A. Mears

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Mears. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Mears. The network helps show where A. Mears may publish in the future.

Co-authorship network of co-authors of A. Mears

This figure shows the co-authorship network connecting the top 25 collaborators of A. Mears. A scholar is included among the top collaborators of A. Mears based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Mears. A. Mears is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Wolfe, Jace, et al.. (2007). 1-Year Postactivation Results for Sequentially Implanted Bilateral Cochlear Implant Users. Otology & Neurotology. 28(5). 589–596. 64 indexed citations
2.
Mears, A., Patricia Creel, J. C. Bendell, et al.. (2007). Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. Journal of Clinical Oncology. 25(18_suppl). 5039–5039. 12 indexed citations
3.
Wolfe, Jace, et al.. (2007). 1-Year Postactivation Results for Sequentially Implanted Bilateral Cochlear Implant Users. Otology & Neurotology. PAP. 3 indexed citations
4.
Stinchcombe, Thomas E., Petra Bůžková, J. K. Choksi, et al.. (2006). A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer. 52(3). 305–311. 8 indexed citations
5.
Stinchcombe, Thomas E., David E. Morris, Dominic T. Moore, et al.. (2006). Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. Lung Cancer. 52(1). 67–74. 24 indexed citations
6.
Socinski, Mark A., Anastasia Ivanova, J. Gerard Wall, et al.. (2005). A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Annals of Oncology. 17(1). 104–109. 34 indexed citations
7.
Stinchcombe, Thomas E., Jaeun Choi, Michael J. Schell, et al.. (2005). Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer. 51(2). 237–243. 13 indexed citations
8.
Stinchcombe, Thomas E., Mark A. Socinski, J. K. Choksi, et al.. (2005). A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7259–7259. 1 indexed citations
9.
Stinchcombe, Thomas E., Mark A. Socinski, J. K. Choksi, et al.. (2005). P-576 A phase I/II trial of weekly docetaxel and gefitinib in elderlypatients (⩾70) with stage IIIB/IV non-small cell lung cancer (NSCLC). Lung Cancer. 49. S270–S270. 1 indexed citations
10.
Socinski, Mark A., David E. Morris, Jan Halle, et al.. (2004). Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal of Clinical Oncology. 22(21). 4341–4350. 123 indexed citations
11.
Niell, Harvey B., et al.. (2004). Randomized phase II trial comparing every-3-week carboplatin/paclitaxel (C/P) versus every-3-week C with weekly P in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7073–7073. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sophie C.J. Bosma Breakdown of academic impact, for papers by Antoine Engelen Breakdown of academic impact, for papers by Zaker Rana Breakdown of academic impact, for papers by W. Hamilton Williams Breakdown of academic impact, for papers by Nathan Farrokhian Breakdown of academic impact, for papers by Josep Jové Breakdown of academic impact, for papers by Eva Clemens Breakdown of academic impact, for papers by Bhisham Chera Breakdown of academic impact, for papers by Matthias Mäurer
Rankless by CCL
2026